Kromek Group plc (AIM:KMK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 49.02M +55.9% |
| Revenue (ttm) | 37.84M +136.8% |
| Net Income | 12.50M |
| EPS | 0.02 |
| Shares Out | 655.30M |
| PE Ratio | 3.87 |
| Forward PE | 19.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,101,597 |
| Open | 8.00 |
| Previous Close | 7.90 |
| Day's Range | 7.48 - 8.00 |
| 52-Week Range | 4.70 - 13.00 |
| Beta | 1.34 |
| Analysts | Strong Buy |
| Price Target | 22.50 (+200.8%) |
| Earnings Date | Sep 16, 2026 |
About Kromek Group
Kromek Group plc, together with its subsidiaries, develops, manufactures, and sells radiation detection components and bio-detection technology solutions for the advanced imaging, CBRN detection, and biological threat detection markets. It offers civil nuclear radiation detection products, which include gamma radiation and neutron detectors, high-specification, high-resolution devices, components, and software for nuclear detection problems, as well as offers a range of radiation detectors that use cadmium zinc telluride (CZT) or scintillator t... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for KMK stock is "Strong Buy." The 12-month stock price target is 23p, which is an increase of 200.80% from the latest price.
News
Kromek Group Share Price at 8p: Can September Results Deliver?
The Kromek Group share price has drifted back to 8.00p as of 26 August 2026, according to Kalkine, a 5.88% decline from the 8.5p level at which shares in the AIM-listed radiation and bio-detection spe...
Kromek Group Earnings release: H2 2026
Kromek Group released its H2 2026 earnings on May 12, 2026, summarizing the period's financial results.
Kromek Group Earnings Call Transcript: H1 2026
Strong growth in the CZT detector market is driving profitability, with major contracts and a shift to a licensing-heavy model. The company targets £60 million revenue and 30% EBITDA margin in the medium term, supported by robust demand in medical imaging and CBRN, while maintaining independence and disciplined capital allocation.
Kromek Group Quarterly report: H1 2026
Kromek Group has published its H1 2026 quarterly earnings report on January 26, 2026.
Kromek Group Earnings Call Transcript: H2 2025
Profitability and revenue growth were driven by the Siemens deal, strong contract wins, and expanding CBRN and biosecurity segments. Gross margin rose to 81%, and the company targets £60M revenue and 30% EBITDA margin by 2030, with continued year-on-year profit expected.
Kromek Group Annual report: H2 2025
Kromek Group has published its H2 2025 annual report on October 3, 2025.